IMMUNE THROMBOCYTOPENIA
Clinical trials for IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with stubborn bleeding disorder
Disease control Recruiting nowThis study is testing a new antibody drug called Anti-CD38 for children aged 6 and up with immune thrombocytopenia (ITP), a condition that causes low platelet counts and bleeding risk. The trial is for kids who haven't gotten better or who relapsed after standard treatments. Rese…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for kids with stubborn bleeding disorder
Disease control Recruiting nowThis study is testing whether a drug called daratumumab works better than rituximab for children with immune thrombocytopenia (ITP), a condition that causes low platelet counts and bleeding risk. The trial is for children aged 6-18 whose ITP didn't improve or came back after stan…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug combo targets stubborn blood disorder in adults
Disease control Recruiting nowThis study is testing whether combining two existing drugs, rituximab and daratumumab, can help adults with a hard-to-treat form of immune thrombocytopenia (ITP). ITP is a condition where the immune system mistakenly attacks platelets, causing a risk of easy bruising and bleeding…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Double-Drug attack tested for stubborn blood disorder
Disease control Recruiting nowThis study is testing whether adding a second drug (anti-CD38) to a standard treatment (rituximab) works better for adults with immune thrombocytopenia (ITP) whose platelet counts stayed low after steroid therapy. Researchers will compare the safety and effectiveness of the two-d…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for stubborn bleeding disorder: trial tests promising drug
Disease control Recruiting nowThis study is testing whether a drug called Daratumumab works better than the standard drug Rituximab for adults with immune thrombocytopenia (ITP), a condition that causes low platelets and bleeding risk. It's for people whose ITP didn't get better or came back after initial ste…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New pill tested to control dangerous low platelet disorder
Disease control Recruiting nowThis study is testing an oral medication called rilzabrutinib for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, increasing bleeding risk. It's for people whose first treatment didn't work well or stopped working. The main goal i…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
First patients test new shot for rare bleeding disorder
Disease control Recruiting nowThis is the first study in people to test a new drug called SHR-2173 for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing a risk of bleeding. The main goal is to check if the injection is safe and well-tolerated. Researcher…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
First-of-its-Kind cell therapy trial targets stubborn blood disorder
Disease control Recruiting nowThis early-stage study is testing a new cell therapy called PRG-1801 for adults with immune thrombocytopenia (ITP) that has come back or hasn't responded to standard treatments. The main goal is to find a safe dose and see if the therapy helps increase platelet counts. Researcher…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC
-
New drug trial targets Hard-to-Treat autoimmune blood diseases
Disease control Recruiting nowThis study is testing an investigational drug called tafasitamab in adults with primary autoimmune blood cell disorders, specifically immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The main goals are to see if the drug is safe and if it can help raise…
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Feb 23, 2026 14:57 UTC
-
New test could pinpoint cause of mysterious low platelet disorder
Diagnosis Recruiting nowThis study is testing whether a specific lab test that looks for antibodies against a person's own platelets can help doctors diagnose immune thrombocytopenia (ITP) faster and more accurately. It will enroll 225 adults who have been found to have low platelet counts. The goal is …
Matched conditions: IMMUNE THROMBOCYTOPENIA
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Mar 23, 2026 15:19 UTC
-
France launches major study to track rare blood disorder patients
Knowledge-focused Recruiting nowThis study is creating a national registry to track 1500 adult patients in France who have immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). The goal is to understand how these rare blood disorders progress in real life and see how well current treatments work …
Matched conditions: IMMUNE THROMBOCYTOPENIA
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC